Dr. Richard D. Hall
Claim this profileUniversity of Virginia Cancer Center
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
17 reported clinical trials
26 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Richard D. Hall is currently running
Fianlimab + Cemiplimab
for Non-Small Cell Lung Cancer
This trial is testing a new drug combination for patients with advanced lung cancer. It aims to see if using two drugs together is more effective than one alone. The study also looks at side effects, how the drugs are processed in the body, and their impact on quality of life.
Recruiting0 awards Phase 2 & 3
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
More about Richard D. Hall
Clinical Trial Related1 year of experience running clinical trials · Led 17 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Richard D. Hall has experience with
- Osimertinib
- Cisplatin
- Pembrolizumab
- Atezolizumab
- Carboplatin
- Cemiplimab
Breakdown of trials Richard D. Hall has run
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Neonatal Abstinence Syndrome
Substance Withdrawal Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Richard D. Hall specialize in?
Richard D. Hall focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Richard D. Hall currently recruiting for clinical trials?
Yes, Richard D. Hall is currently recruiting for 10 clinical trials in Charlottesville Virginia. If you're interested in participating, you should apply.
Are there any treatments that Richard D. Hall has studied deeply?
Yes, Richard D. Hall has studied treatments such as Osimertinib, Cisplatin, Pembrolizumab.
What is the best way to schedule an appointment with Richard D. Hall?
Apply for one of the trials that Richard D. Hall is conducting.
What is the office address of Richard D. Hall?
The office of Richard D. Hall is located at: University of Virginia Cancer Center, Charlottesville, Virginia 22908 United States. This is the address for their practice at the University of Virginia Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.